Genmab
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Genmab and other ETFs, options, and stocks.About GMAB
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
CEOJan G. J. van de Winkel
CEOJan G. J. van de Winkel
Employees3,029
Employees3,029
HeadquartersCopenhagen, Central Denmark
HeadquartersCopenhagen, Central Denmark
Founded1998
Founded1998
Employees3,029
Employees3,029
GMAB Key Statistics
Market cap17.97B
Market cap17.97B
Price-Earnings ratio21.72
Price-Earnings ratio21.72
Dividend yield—
Dividend yield—
Average volume2.45M
Average volume2.45M
High today$29.29
High today$29.29
Low today$28.78
Low today$28.78
Open price$28.99
Open price$28.99
Volume1.74M
Volume1.74M
52 Week high$35.43
52 Week high$35.43
52 Week low$21.00
52 Week low$21.00
GMAB News
Investing.com 3d
H.C. Wainwright reiterates Genmab stock rating on FDA approval - Investing.com...
Analyst ratings
86%
of 28 ratingsBuy
85.7%
Hold
14.3%
Sell
0%
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.